The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Esophageal Neoplasms

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Esophageal Neoplasms


Psychiatry related information on Esophageal Neoplasms


High impact information on Esophageal Neoplasms


Chemical compound and disease context of Esophageal Neoplasms


Biological context of Esophageal Neoplasms


Anatomical context of Esophageal Neoplasms


Gene context of Esophageal Neoplasms


Analytical, diagnostic and therapeutic context of Esophageal Neoplasms


  1. Gastroesophageal reflux, barrett esophagus, and esophageal cancer: scientific review. Shaheen, N., Ransohoff, D.F. JAMA (2002) [Pubmed]
  2. Tylosis esophageal cancer locus on chromosome 17q25.1 is commonly deleted in sporadic human esophageal cancer. Iwaya, T., Maesawa, C., Ogasawara, S., Tamura, G. Gastroenterology (1998) [Pubmed]
  3. Prevention of esophageal cancer: the nutrition intervention trials in Linxian, China. Linxian Nutrition Intervention Trials Study Group. Taylor, P.R., Li, B., Dawsey, S.M., Li, J.Y., Yang, C.S., Guo, W., Blot, W.J. Cancer Res. (1994) [Pubmed]
  4. E-cadherin and alpha-catenin expression in human esophageal cancer. Kadowaki, T., Shiozaki, H., Inoue, M., Tamura, S., Oka, H., Doki, Y., Iihara, K., Matsui, S., Iwazawa, T., Nagafuchi, A. Cancer Res. (1994) [Pubmed]
  5. Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer. Ilson, D.H., Bains, M., Kelsen, D.P., O'Reilly, E., Karpeh, M., Coit, D., Rusch, V., Gonen, M., Wilson, K., Minsky, B.D. J. Clin. Oncol. (2003) [Pubmed]
  6. SULT1A1 polymorphism and esophageal cancer in males. Wu, M.T., Wang, Y.T., Ho, C.K., Wu, D.C., Lee, Y.C., Hsu, H.K., Kao, E.L., Lee, J.M. Int. J. Cancer (2003) [Pubmed]
  7. Proliferation of esophageal epithelial cells among residents of Linxian, People's Republic of China. Yang, G.C., Lipkin, M., Yang, K., Wang, G.Q., Li, J.Y., Yang, C.S., Winawer, S., Newmark, H., Blot, W.J., Fraumeni, J.F. J. Natl. Cancer Inst. (1987) [Pubmed]
  8. Vitamin A and other deficiencies in Linxian, a high esophageal cancer incidence area in northern China. Yang, C.S., Sun, Y., Yang, Q.U., Miller, K.W., Li, G.Y., Zheng, S.F., Ershow, A.G., Blot, W.J., Li, J.Y. J. Natl. Cancer Inst. (1984) [Pubmed]
  9. Zinc deficiency, alcohol, and retinoid: association with esophageal cancer in rats. Gabrial, G.N., Schrager, T.F., Newberne, P.M. J. Natl. Cancer Inst. (1982) [Pubmed]
  10. Zinc deficiency and methylbenzylnitrosamine-induced esophageal cancer in rats. Fong, L.Y., Sivak, A., Newberne, P.M. J. Natl. Cancer Inst. (1978) [Pubmed]
  11. Bile acids induce ectopic expression of intestinal guanylyl cyclase C Through nuclear factor-kappaB and Cdx2 in human esophageal cells. Debruyne, P.R., Witek, M., Gong, L., Birbe, R., Chervoneva, I., Jin, T., Domon-Cell, C., Palazzo, J.P., Freund, J.N., Li, P., Pitari, G.M., Schulz, S., Waldman, S.A. Gastroenterology (2006) [Pubmed]
  12. Endoscopic local injection of a new drug-delivery format of peplomycin for superficial esophageal cancer: a pilot study. Hagiwara, A., Takahashi, T., Kojima, O., Kitamura, K., Sakakura, C., Shoubayashi, S., Osaki, K., Iwamoto, A., Lee, M., Fujita, K. Gastroenterology (1993) [Pubmed]
  13. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Buttar, N.S., Wang, K.K., Leontovich, O., Westcott, J.Y., Pacifico, R.J., Anderson, M.A., Krishnadath, K.K., Lutzke, L.S., Burgart, L.J. Gastroenterology (2002) [Pubmed]
  14. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. Ilson, D.H., Saltz, L., Enzinger, P., Huang, Y., Kornblith, A., Gollub, M., O'Reilly, E., Schwartz, G., DeGroff, J., Gonzalez, G., Kelsen, D.P. J. Clin. Oncol. (1999) [Pubmed]
  15. Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy. Adelstein, D.J., Rice, T.W., Rybicki, L.A., Larto, M.A., Ciezki, J., Saxton, J., DeCamp, M., Vargo, J.J., Dumot, J.A., Zuccaro, G. J. Clin. Oncol. (2000) [Pubmed]
  16. Urinary excretion of N-nitrosamino acids and nitrate by inhabitants of high- and low-risk areas for esophageal cancer in Northern China: endogenous formation of nitrosoproline and its inhibition by vitamin C. Lu, S.H., Ohshima, H., Fu, H.M., Tian, Y., Li, F.M., Blettner, M., Wahrendorf, J., Bartsch, H. Cancer Res. (1986) [Pubmed]
  17. Reduction to homozygosity involving p53 in esophageal cancers demonstrated by the polymerase chain reaction. Meltzer, S.J., Yin, J., Huang, Y., McDaniel, T.K., Newkirk, C., Iseri, O., Vogelstein, B., Resau, J.H. Proc. Natl. Acad. Sci. U.S.A. (1991) [Pubmed]
  18. Combined cyclin D1 overexpression and zinc deficiency disrupts cell cycle and accelerates mouse forestomach carcinogenesis. Fong, L.Y., Mancini, R., Nakagawa, H., Rustgi, A.K., Huebner, K. Cancer Res. (2003) [Pubmed]
  19. Two functional coding single nucleotide polymorphisms in STK15 (Aurora-A) coordinately increase esophageal cancer risk. Kimura, M.T., Mori, T., Conroy, J., Nowak, N.J., Satomi, S., Tamai, K., Nagase, H. Cancer Res. (2005) [Pubmed]
  20. p53 tumor suppressor gene mutation in early esophageal precancerous lesions and carcinoma among high-risk populations in Henan, China. Gao, H., Wang, L.D., Zhou, Q., Hong, J.Y., Huang, T.Y., Yang, C.S. Cancer Res. (1994) [Pubmed]
  21. Coexpression of cyclooxygenases (COX-1, COX-2) and vascular endothelial growth factors (VEGF-A, VEGF-C) in esophageal adenocarcinoma. von Rahden, B.H., Stein, H.J., Pühringer, F., Koch, I., Langer, R., Piontek, G., Siewert, J.R., Höfler, H., Sarbia, M. Cancer Res. (2005) [Pubmed]
  22. Coexpression of Grb7 with epidermal growth factor receptor or Her2/erbB2 in human advanced esophageal carcinoma. Tanaka, S., Mori, M., Akiyoshi, T., Tanaka, Y., Mafune, K., Wands, J.R., Sugimachi, K. Cancer Res. (1997) [Pubmed]
  23. Effects of glutamine supplements and radiochemotherapy on systemic immune and gut barrier function in patients with advanced esophageal cancer. Yoshida, S., Matsui, M., Shirouzu, Y., Fujita, H., Yamana, H., Shirouzu, K. Ann. Surg. (1998) [Pubmed]
  24. Proliferation potential-related protein, an ideal esophageal cancer antigen for immunotherapy, identified using complementary DNA microarray analysis. Yoshitake, Y., Nakatsura, T., Monji, M., Senju, S., Matsuyoshi, H., Tsukamoto, H., Hosaka, S., Komori, H., Fukuma, D., Ikuta, Y., Katagiri, T., Furukawa, Y., Ito, H., Shinohara, M., Nakamura, Y., Nishimura, Y. Clin. Cancer Res. (2004) [Pubmed]
  25. AIS overexpression in advanced esophageal cancer. Hibi, K., Nakayama, H., Taguchi, M., Kasai, Y., Ito, K., Akiyama, S., Nakao, A. Clin. Cancer Res. (2001) [Pubmed]
  26. Intragenic mutations of CDKN2B and CDKN2A in primary human esophageal cancers. Suzuki, H., Zhou, X., Yin, J., Lei, J., Jiang, H.Y., Suzuki, Y., Chan, T., Hannon, G.J., Mergner, W.J., Abraham, J.M. Hum. Mol. Genet. (1995) [Pubmed]
  27. Cyclooxygenase-2 expression in human esophageal carcinoma. Zimmermann, K.C., Sarbia, M., Weber, A.A., Borchard, F., Gabbert, H.E., Schrör, K. Cancer Res. (1999) [Pubmed]
  28. Preferential expression of the third immunoglobulin-like domain of K-sam product provides keratinocyte growth factor-dependent growth in carcinoma cell lines. Ishii, H., Hattori, Y., Itoh, H., Kishi, T., Yoshida, T., Sakamoto, H., Oh, H., Yoshida, S., Sugimura, T., Terada, M. Cancer Res. (1994) [Pubmed]
  29. Overexpression of CDC25B overrides radiation-induced G2-M arrest and results in increased apoptosis in esophageal cancer cells. Miyata, H., Doki, Y., Yamamoto, H., Kishi, K., Takemoto, H., Fujiwara, Y., Yasuda, T., Yano, M., Inoue, M., Shiozaki, H., Weinstein, I.B., Monden, M. Cancer Res. (2001) [Pubmed]
  30. Macrophage migration inhibitory factor stimulates angiogenic factor expression and correlates with differentiation and lymph node status in patients with esophageal squamous cell carcinoma. Ren, Y., Law, S., Huang, X., Lee, P.Y., Bacher, M., Srivastava, G., Wong, J. Ann. Surg. (2005) [Pubmed]
  31. Phase I trial of combined-modality therapy for localized esophageal cancer: escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy. Brenner, B., Ilson, D.H., Minsky, B.D., Bains, M.S., Tong, W., Gonen, M., Kelsen, D.P. J. Clin. Oncol. (2004) [Pubmed]
  32. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. Ilson, D.H., Ajani, J., Bhalla, K., Forastiere, A., Huang, Y., Patel, P., Martin, L., Donegan, J., Pazdur, R., Reed, C., Kelsen, D.P. J. Clin. Oncol. (1998) [Pubmed]
  33. Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. van Westreenen, H.L., Westerterp, M., Bossuyt, P.M., Pruim, J., Sloof, G.W., van Lanschot, J.J., Groen, H., Plukker, J.T. J. Clin. Oncol. (2004) [Pubmed]
  34. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study--JCOG9204. Ando, N., Iizuka, T., Ide, H., Ishida, K., Shinoda, M., Nishimaki, T., Takiyama, W., Watanabe, H., Isono, K., Aoyama, N., Makuuchi, H., Tanaka, O., Yamana, H., Ikeuchi, S., Kabuto, T., Nagai, K., Shimada, Y., Kinjo, Y., Fukuda, H. J. Clin. Oncol. (2003) [Pubmed]
  35. Chemoprevention of N-nitrosomethylbenzylamine-induced esophageal cancer in rats by the naturally occurring thioether, diallyl sulfide. Wargovich, M.J., Woods, C., Eng, V.W., Stephens, L.C., Gray, K. Cancer Res. (1988) [Pubmed]
WikiGenes - Universities